Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01442896
Other study ID # 111223
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2011
Est. completion date December 18, 2015

Study information

Verified date January 2024
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to perform exploratory analyses to evaluate rates of functional and structural change in glaucoma, to identify predictors of rapid progression in patients with glaucoma and to identify possible genetic factors and biomarkers associated with the disease.


Description:

PRIMARY OBJECTIVES To identify and combine a set of predictors (i.e. by statistical modeling, machine learning classifiers or neural networks) to predict progression in glaucoma patients To determine how to most sensitively and specifically determine progression for a trial of a potential neuroprotective agent. SECONDARY OBJECTIVES To evaluate genetic and other potential biomarkers associated with progression in glaucoma. To evaluate tests currently used on glaucoma patients to better predict which ones are most sensitive to detect disease progression and measure rates of change. To assess progression by structural and functional tests: - Optic disc stereophotographs - Cirrus OCT - RTVue OCT - Standard Automated Perimetry (SAP) - Frequency Doubling Technology Matrix


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date December 18, 2015
Est. primary completion date December 18, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility INCLUSION CRITERIA Subjects will be eligible if the following criteria are met: - Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past 3 years and high IOP (IOP above target), disc hemorrhage (within 3 years), family history of glaucoma-related vision loss or thin central cornea (<510um), - Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy - For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery - Best corrected visual acuity of 20/40 or better at enrollment - Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP < 22mmHg o Normal appearing optic disc and no evidence of optic disc damage - Ability to provide written informed consent for participation in this study EXCLUSION CRITERIA Subjects who meet any of the following criteria will be excluded from this study: - Subjects with an ocular disease other than glaucoma - Subjects participating in a long-term interventional clinical trial - Subjects with any other medical condition which would prohibit them from making all study visits within the 24 months - Glaucoma patients who have not demonstrated disease progression in the past 3 years - Patients with diagnosis of pigmentary dispersion syndrome/glaucoma - Patients that have had glaucoma surgery and have IOP = 12 mm Hg - Patients with advanced glaucoma with MD = -20 dB - Patients with a history of LASIK surgery - Patients with myopia > -6.0 diopters. - Patients with hyperopia >+6.0 diopters. - In the investigator's opinion, any patient that cannot satisfactorily complete all of the structural and functional testing included in the protocol (investigator determined) - Unable to perform reliable VF testing (Fixation losses 33% or less, false negative rate 33% or less and false positive rate of 15% or less) at the time of study entry - In the investigator's opinion, any patient with an ocular disease that could impact study assessments - Patients with cataracts in which surgery is planned or anticipated within the next 3 months. - Patients with narrow angles in which laser iridotomy is planned or anticipated within the next 3 months.

Study Design


Locations

Country Name City State
United States Hamilton Glaucoma Center, UCSD La Jolla California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Diego Genentech, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (4)

Alencar LM, Zangwill LM, Weinreb RN, Bowd C, Vizzeri G, Sample PA, Susanna R Jr, Medeiros FA. Agreement for detecting glaucoma progression with the GDx guided progression analysis, automated perimetry, and optic disc photography. Ophthalmology. 2010 Mar;117(3):462-70. doi: 10.1016/j.ophtha.2009.08.012. Epub 2009 Dec 24. — View Citation

Medeiros FA, Alencar LM, Sample PA, Zangwill LM, Susanna R Jr, Weinreb RN. The relationship between intraocular pressure reduction and rates of progressive visual field loss in eyes with optic disc hemorrhage. Ophthalmology. 2010 Nov;117(11):2061-6. doi: 10.1016/j.ophtha.2010.02.015. Epub 2010 Jun 11. — View Citation

Medeiros FA, Alencar LM, Zangwill LM, Sample PA, Weinreb RN. The Relationship between intraocular pressure and progressive retinal nerve fiber layer loss in glaucoma. Ophthalmology. 2009 Jun;116(6):1125-33.e1-3. doi: 10.1016/j.ophtha.2008.12.062. Epub 2009 Apr 19. — View Citation

Medeiros FA, Zangwill LM, Alencar LM, Bowd C, Sample PA, Susanna R Jr, Weinreb RN. Detection of glaucoma progression with stratus OCT retinal nerve fiber layer, optic nerve head, and macular thickness measurements. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5741-8. doi: 10.1167/iovs.09-3715. Epub 2009 Oct 8. — View Citation

See also
  Status Clinical Trial Phase
Recruiting NCT05564091 - Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma N/A
Recruiting NCT02792803 - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Phase 4
Terminated NCT02801617 - Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Phase 3
Completed NCT01384149 - EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA Phase 1
Completed NCT00300079 - Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Phase 4
Enrolling by invitation NCT00221923 - African Descent and Glaucoma Evaluation Study
Recruiting NCT05605743 - Alternate Nostril Breathing Training in Geriatrics With Glaucoma and High Blood Pressure N/A
Completed NCT04828057 - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Enrolling by invitation NCT05557721 - Uddevalla Skövde Transscleral Micropulse Study
Recruiting NCT04595227 - Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
Terminated NCT04141865 - Effect of Xen Implantation on the Aqueous Humor Proteome
Completed NCT01979913 - An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Phase 4
Completed NCT01943721 - A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension Phase 1
Completed NCT02023242 - Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes N/A
Not yet recruiting NCT01711177 - Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma N/A
Completed NCT01769521 - Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG N/A
Recruiting NCT00773877 - Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients N/A
Recruiting NCT00773123 - Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma. N/A
Completed NCT02544646 - Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG N/A
Recruiting NCT04736264 - Malay Glaucoma Eye Study II Navigation, Mobility and Reading Ability in Primary Glaucoma N/A